Trial · NCT03512262
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD at Month 12 | Abaloparatide | 8.4820 | Standard Error 0.5353 | percent change | |
| Percent Change From Baseline in Lumbar Spine BMD at Month 12 | Placebo | 1.1654 | Standard Error 0.7235 | percent change | |
| Percent Change From Baseline in Total Hip BMD at Month 12 | Abaloparatide | 2.1351 | Standard Error 0.2711 | percent change | |
| Percent Change From Baseline in Total Hip BMD at Month 12 | Placebo | 0.0143 | Standard Error 0.3543 | percent change | |
| Percent Change From Baseline in Femoral Neck BMD at Month 12 | Abaloparatide | 2.9766 | Standard Error 0.3448 | percent change | |
| Percent Change From Baseline in Femoral Neck BMD at Month 12 | Placebo | 0.1545 | Standard Error 0.4527 | percent change | |
| Percent Change From Baseline in Lumbar Spine BMD at Month 6 | Abaloparatide | 5.5436 | Standard Error 0.4127 | percent change | |
| Percent Change From Baseline in Lumbar Spine BMD at Month 6 | Placebo | 0.6418 | Standard Error 0.5472 | percent change | |
| Percent Change in Total Hip BMD From Baseline at Month 6 | Abaloparatide | 1.3888 | Standard Error 0.2142 | percent change | |
| Percent Change in Total Hip BMD From Baseline at Month 6 | Placebo | 0.0267 | Standard Error 0.2790 | percent change | |
| Percent Change From Baseline in Femoral Neck BMD at Month 6 | Abaloparatide | 1.4790 | Standard Error 0.2714 | percent change | |
| Percent Change From Baseline in Femoral Neck BMD at Month 6 | Placebo | -0.1884 | Standard Error 0.3569 | percent change | |
| Percent Change From Baseline in Ultra-Distal Radius BMD at Month 12 | Abaloparatide | 1.4358 | Standard Error 0.4236 | percent change | |
| Percent Change From Baseline in Ultra-Distal Radius BMD at Month 12 | Placebo | -0.1915 | Standard Error 0.5722 | percent change | |
| Percent Change From Baseline in Distal One-third Radius BMD at Month 12 | Abaloparatide | -0.0138 | Standard Error 0.3253 | percent change | |
| Percent Change From Baseline in Distal One-third Radius BMD at Month 12 | Placebo | 0.7066 | Standard Error 0.4285 | percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N-terminal Propeptide (s-PINP) at Month 12 | Abaloparatide | 225.919 | Standard Deviation 416.4173 | percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N-terminal Propeptide (s-PINP) at Month 12 | Placebo | 0.291 | Standard Deviation 31.8038 | percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Month 12 | Abaloparatide | 89.639 | Standard Deviation 206.7227 | percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Month 12 | Placebo | 15.359 | Standard Deviation 40.3351 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03512262/results